Advanced Therapies in Crohn's Disease

BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (APPROVED BY HEALTH CANADA FOR IBD INDICATIONS)

Stelara®/Johnson & Johnson Innovative Medicine/BioAdvance® (CD 2017, UC 2020)
Wezlana/Amgen/Entrust (2025)
Steqeyma/Celltrion/Celltrion Connect (2024)
Otulfi®/Fresenius Kabi/KabiCare® (2024)

CLASS

Monoclonal antibody interleukin (IL)-12/23 inhibitor

ACTION

Targets an overactive immune system by blocking two receptors called IL-12 and IL-23. By blocking these receptors, cells are slowed down, which reduces inflammation.